Loading…
ARS Pharmaceuticals, Inc. is projected to rise to $8.66 by 2027, a +2% move from its current price of $8.50. SPRY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.22 | $8.49 | $8.78 | -0.08% |
| May 30 | $8.10 | $8.49 | $8.89 | -0.15% |
| May 31 | $8.01 | $8.48 | $8.98 | -0.23% |
| Jun 1 | $7.94 | $8.47 | $9.05 | -0.30% |
| Jun 2 | $7.87 | $8.47 | $9.11 | -0.37% |
| Jun 3 | $7.81 | $8.46 | $9.17 | -0.45% |
| Jun 4 | $7.75 | $8.46 | $9.22 | -0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.75 | $8.46 | $9.22 | -0.52% |
| Week 2 | $7.44 | $8.41 | $9.51 | -1.05% |
| Week 3 | $7.20 | $8.37 | $9.73 | -1.56% |
| Week 4 | $7.00 | $8.32 | $9.90 | -2.08% |
| Week 5 | $6.82 | $8.28 | $10.05 | -2.59% |
| Week 6 | $6.66 | $8.24 | $10.19 | -3.10% |
| Week 7 | $6.51 | $8.19 | $10.31 | -3.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ARS Pharmaceuticals, Inc. (SPRY) operates in the Healthcare sector as a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions in the United States and internationally.
The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
ARS Pharmaceuticals was founded in 2015 and is headquartered in San Diego, California.
SPRY is currently priced at $8.50 per share and trades with a market position reflecting a market cap of $844.08M. It is ranked 2630 in the current capitalization landscape.
Looking forward, the forecasted path shows upside potential, with an average price of $11.78 in 2030 and $45.08 on average by 2050. The implied ROIs are 38.6% by 2030 and 430.4% by 2050, with sentiment shifting to BULLISH in the later years.
A major floor 27.0% below — a decisive break under it would weaken the trend.
The nearest floor, 15.6% below — buyers have tended to step in here.
The nearest ceiling, 9.2% above — a clean break opens room to run.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key SPRY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.13 | Buy | $8.15 | Buy |
| MA 10 | $7.85 | Buy | $8.08 | Buy |
| MA 20 | $8.26 | Buy | $8.14 | Buy |
| MA 50 | $8.19 | Buy | $8.36 | Buy |
| MA 100 | $9.05 | Sell | $8.89 | Sell |
| MA 200 | $9.76 | Sell | $9.86 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.59 | Neutral |
| Stoch RSI (14) | 80.58 | Sell |
| CCI (20) | 32.92 | Neutral |
| Williams %R (14) | -27.32 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.75 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 72.68 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 61.78 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 8.39 | Buy |
| ADX (14) | 13.61 | Neutral |
| ATR (14) | 0.27 | Info |
The 30-day technical picture is bullish. RSI14 stands at 50 as a neutral midpoint in the near term, with a bullish tilt in price action.
Key moving averages and levels show the near-term structure: SMA50 is $8.19 and SMA200 is $9.76, providing nearby dynamic resistance and support. A clear support level sits at $7.17 and a resistance level at $9.28, while the 30-day range stretches from $6.85 to $10.55.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.17 | $8.50 | $10.88 | 0% | Neutral | |
| $6.74 | $8.66 | $11.88 | +2% | Neutral | |
| $6.58 | $8.75 | $12.51 | +3% | Neutral | |
| $6.74 | $9.21 | $13.61 | +8% | Neutral | |
| $8.40 | $11.78 | $17.89 | +39% | Bullish | |
| $9.26 | $13.28 | $20.66 | +56% | Bullish | |
| $9.28 | $13.61 | $21.64 | +60% | Bullish | |
| $9.35 | $13.99 | $22.68 | +65% | Bullish | |
| $8.87 | $13.54 | $22.34 | +59% | Bullish | |
| $9.60 | $14.92 | $25.04 | +76% | Bullish | |
| $12.04 | $20.40 | $36.70 | +140% | Bullish | |
| $22.86 | $45.08 | $89.69 | +430% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.17 | $8.50 | $10.01 | +0.00% |
| June 2026 | $7.00 | $8.25 | $9.99 | -2.92% |
| July 2026 | $6.66 | $7.94 | $9.77 | -3.81% |
| August 2026 | $6.70 | $8.05 | $10.03 | +1.41% |
| September 2026 | $6.70 | $8.10 | $10.19 | +0.67% |
| October 2026 | $6.48 | $7.89 | $10.01 | -2.67% |
| November 2026 | $6.54 | $8.00 | $10.24 | +1.46% |
| December 2026 | $6.87 | $8.44 | $10.88 | +5.52% |
Click any year to see its month-by-month SPRY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SPRY could reach as high as $10.88, with a base case around $8.50 and support toward $7.17 — roughly 0% from $8.50. A consolidation phase looks the most probable path here.
Expect SPRY to range from $6.74 to $11.88 through 2027. The $8.66 average target implies a +2% move from current prices. That is up +2% on the projected 2026 average. Price action looks broadly range-bound.
The SPRY price prediction for 2028 points to an average of $8.75 (low $6.58, high $12.51) — a potential gain of +3% on today's $8.50. A consolidation phase looks the most probable path here.
In 2029, SPRY is projected to trade between $6.74 and $13.61, averaging $9.21 — a potential gain of +8% from today's $8.50. That is up +5% on the projected 2028 average. Price action looks broadly range-bound.
ARS Pharmaceuticals, Inc.'s 2030 outlook centres on $11.78, within a $8.40 to $17.89 range. That is up +28% on the projected 2029 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SPRY could reach as high as $20.66, with a base case around $13.28 and support toward $9.26 — roughly +56% from $8.50. Momentum favours further upside here.
Expect SPRY to range from $9.28 to $21.64 through 2032. The $13.61 average target implies a +60% move from current prices. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SPRY price prediction for 2033 points to an average of $13.99 (low $9.35, high $22.68) — a potential gain of +65% on today's $8.50. Momentum favours further upside here.
In 2034, SPRY is projected to trade between $8.87 and $22.34, averaging $13.54 — a potential gain of +59% from today's $8.50. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
ARS Pharmaceuticals, Inc.'s 2035 outlook centres on $14.92, within a $9.60 to $25.04 range. That is up +10% on the projected 2034 average. That marks a +76% change versus current levels. Momentum favours further upside here.
By 2040, SPRY could reach as high as $36.70, with a base case around $20.40 and support toward $12.04 — roughly +140% from $8.50. Buyers look set to stay in control over this stretch.
Expect SPRY to range from $22.86 to $89.69 through 2050. The $45.08 average target implies a +430% move from current prices. That is up +121% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SPRY today (≈ 117.647059 SPRY) could be worth
$5,303.64
+$4,303.64 (+430%) by 2050 · US Dollar
Based on the average projected SPRY price of $45.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPRYwould be worth at today's price.
$1,000 invested in SPRY on May 27, 2025 (≈ 68.399453 SPRY) would be worth
$581.4
-$418.6 (-41.9%) today · 0.58× · US Dollar
Based on a SPRY entry price of $14.62 vs. today's $8.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.8 | $1,089.74 | +9.0% |
| 1 month ago | $7.95 | $1,069.18 | +6.9% |
| 3 months ago | $9.34 | $910.06 | -9.0% |
| 6 months ago | $9.54 | $890.99 | -10.9% |
| 1 year ago | $14.62 | $581.4 | -41.9% |
| All time (5.0y) ago | $28.83 | $294.83 | -70.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRY forecast.
Our base-case forecast reaches $17.00 around 2040.
Implied market cap at $17.00: $1.69B
From 2026 through 2029, the forecast shows neutral sentiment with gradual price growth: the 2026 average is $8.50 and the 2029 average is $9.21.
By 2030, the average price is forecast at $11.78 with a 38.6% ROI, signaling a bullish turn in the outlook.
Through 2031-2035, the averages rise to $13.28, $13.61, $13.99, and $13.54 with ROIs of 56.2%, 60.1%, 64.6%, and 59.3% respectively, under a continuing bullish stance.
In 2040 the average is forecast at $20.40 with a 140% ROI, and by 2050 the average climbs to $45.08 with a 430.4% ROI. The sentiment remains BULLISH across the long horizon. These are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $11.78 and a max of $17.89 with a min of $8.40; ROI 38.6% and sentiment BULLISH.
Forecasts show bullish sentiment from 2030 onward with ROI reaching 430.4% by 2050, though earlier years (2026-2029) show neutral sentiment and more modest growth.
Yes. The forecast shows higher-end outcomes with a max of $89.69 by 2050.
Current price is $8.50 and market cap is $844.08M.
The 30-day range is from $6.85 to $10.55.
ARS Pharmaceuticals, Inc. Community Discussion
0Share your ARS Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.